SK bioscienceLtd Future Growth
Future criteria checks 0/6
SK bioscienceLtd's revenue and earnings are forecast to decline at 4.8% and 18.5% per annum respectively. EPS is expected to decline by 18.2% per annum. Return on equity is forecast to be -0.2% in 3 years.
Key information
-18.5%
Earnings growth rate
-18.2%
EPS growth rate
Biotechs earnings growth | 47.6% |
Revenue growth rate | -4.8% |
Future return on equity | -0.2% |
Analyst coverage | Good |
Last updated | 03 May 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 308,039 | 33,929 | -5,000 | 15,000 | 3 |
12/31/2025 | 324,788 | -16,206 | -117,780 | 23,967 | 8 |
12/31/2024 | 241,962 | -37,406 | -11,000 | -11,000 | 7 |
12/31/2023 | 369,506 | 22,318 | -20,949 | 29,346 | N/A |
9/30/2023 | 419,202 | 45,890 | -32,868 | 11,613 | N/A |
6/30/2023 | 278,429 | 18,276 | -162,430 | -123,743 | N/A |
3/31/2023 | 390,231 | 80,378 | -107,916 | -47,766 | N/A |
12/31/2022 | 456,726 | 122,452 | -201,448 | -124,958 | N/A |
12/31/2021 | 929,001 | 355,139 | 492,124 | 536,594 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A302440's earnings are forecast to decline over the next 3 years (-18.5% per year).
Earnings vs Market: A302440's earnings are forecast to decline over the next 3 years (-18.5% per year).
High Growth Earnings: A302440's earnings are forecast to decline over the next 3 years.
Revenue vs Market: A302440's revenue is expected to decline over the next 3 years (-4.8% per year).
High Growth Revenue: A302440's revenue is forecast to decline over the next 3 years (-4.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A302440 is forecast to be unprofitable in 3 years.